J. Goldman & CO LP Cyclacel Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

  • $3.27 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$8.02 - $11.0 $3.55 Million - $4.87 Million
-442,315 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$7.59 - $10.48 $643,563 - $888,609
84,791 Added 23.72%
442,315 $2.62 Million
Q1 2021

May 17, 2021
BUY
$6.86 - $9.24 $2.45 Million - $3.3 Million
357,524 New
357,524 $2.54 Million

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email